Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in two upcoming virtual investor conferences in April:
-
21st Annual Needham Virtual Healthcare Conference
Format: Panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space”
Date/Time: Thursday, April 14, 2022 at 11:00 a.m. ET
Location: Virtual
-
Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Format: Fireside Chat
Date/Time: Tuesday, April 26, 2022 at 9 a.m. ET
Location: Virtual
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005054/en/
Contacts
Investor:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com
